#1 Clinical Trials Search in Europe

Paltusotine

Paltusotine, also known as CRN00808, is an oral medication being studied in clinical trials for the treatment of acromegaly and carcinoid syndrome. This article explores the ongoing research into Paltusotine’s safety, effectiveness, and potential benefits for patients with these conditions.

Table of Contents

What is Paltusotine?

Paltusotine, also known by its former name CRN00808, is a new medication being studied for the treatment of certain hormonal disorders[1]. It is an oral selective nonpeptide somatostatin receptor type 2 biased agonist. In simpler terms, this means that Paltusotine is a drug taken by mouth that targets specific receptors in the body involved in hormone regulation[2].

What Conditions Does Paltusotine Treat?

Paltusotine is primarily being studied for two main conditions:

  1. Acromegaly: This is a hormonal disorder that occurs when the body produces too much growth hormone, usually due to a benign tumor in the pituitary gland. It can cause enlargement of bones, especially in the hands, feet, and face[3].
  2. Carcinoid Syndrome: This is a group of symptoms that can occur in people with certain types of slow-growing cancerous tumors, called carcinoid tumors. These tumors most commonly occur in the digestive tract or lungs and can release hormones that cause flushing, diarrhea, and other symptoms[6].

How Does Paltusotine Work?

Paltusotine works by mimicking the action of somatostatin, a natural hormone in the body that regulates the release of several other hormones. By binding to somatostatin receptors, particularly type 2, Paltusotine can help control the excessive hormone production that occurs in conditions like acromegaly and carcinoid syndrome[4].

In acromegaly, Paltusotine aims to reduce the levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1), which are typically elevated in this condition. For carcinoid syndrome, it may help control the release of hormones from carcinoid tumors that cause symptoms[6].

How is Paltusotine Administered?

One of the key advantages of Paltusotine is its method of administration. Unlike some other treatments for these conditions that require injections, Paltusotine is taken orally, once daily. It comes in the form of tablets or capsules, making it more convenient for patients[5].

Clinical Trials and Research

Paltusotine is currently being studied in several clinical trials:

  • ACROBAT Advance: A long-term study evaluating the safety and efficacy of Paltusotine in people with acromegaly[1].
  • ACROBAT Edge: An open-label study looking at Paltusotine in acromegaly patients already treated with other somatostatin analogues[2].
  • PATHFNDR-2: A study of Paltusotine in acromegaly patients who haven’t received drug treatment before[3].
  • PATHFNDR-1: A study comparing Paltusotine to placebo in acromegaly patients previously treated with long-acting somatostatin receptor ligands[4].
  • ACROBAT Evolve: A study evaluating Paltusotine in acromegaly patients who respond well to certain other treatments[5].
  • A study for patients with carcinoid syndrome, evaluating different doses of Paltusotine[6].

Safety and Efficacy

The primary goal of many of these studies is to assess the safety and efficacy of Paltusotine. Researchers are looking at several key factors:

  • Safety: They’re monitoring the incidence of treatment-emergent adverse events (TEAEs), which are any unfavorable and unintended signs, symptoms, or diseases that occur during the treatment period[1].
  • Efficacy in Acromegaly: This is primarily measured by changes in IGF-1 and GH levels. The goal is to reduce these levels to normal or near-normal ranges[2][3].
  • Symptom Improvement: Some studies are using tools like the Acromegaly Symptoms Diary (ASD) to assess changes in patient-reported symptoms[3].
  • Efficacy in Carcinoid Syndrome: For this condition, researchers are looking at how different doses of Paltusotine affect symptoms[6].

Future Prospects

While Paltusotine is still in the research phase and not yet approved for general use, the ongoing clinical trials are providing valuable information about its potential benefits and risks. If these studies continue to show positive results, Paltusotine could become an important new treatment option for people with acromegaly and carcinoid syndrome, offering the convenience of oral administration and potentially improved symptom control[4][6].

Aspect Details
Drug Name Paltusotine (CRN00808)
Administration Oral, once daily
Primary Conditions Studied Acromegaly, Carcinoid Syndrome
Key Outcome Measures IGF-1 levels, GH levels, Adverse events, Acromegaly symptoms
Study Designs Open-label, Randomized controlled, Placebo-controlled
Study Durations Varying from 8 weeks to 312 weeks
Dosages Studied 40 mg, 80 mg (with potential escalation)

FAQ

  • What is Paltusotine? Paltusotine is an oral medication that acts as a selective nonpeptide somatostatin receptor type 2 biased agonist. It is being studied as a potential treatment for acromegaly and carcinoid syndrome.
  • How is Paltusotine administered? Paltusotine is taken once daily by mouth, either as capsules or tablets, depending on the specific clinical trial.
  • What conditions is Paltusotine being studied for? Paltusotine is primarily being studied for the treatment of acromegaly. Additionally, there is ongoing research into its potential use for carcinoid syndrome.
  • What are the main outcomes being measured in Paltusotine clinical trials? The main outcomes being measured include changes in insulin-like growth factor-1 (IGF-1) levels, growth hormone (GH) levels, safety and tolerability through monitoring adverse events, and improvements in acromegaly symptoms.
  • How long do the Paltusotine clinical trials typically last? The duration of Paltusotine clinical trials varies, with some studies lasting up to 312 weeks (6 years) for long-term safety and efficacy evaluation, while others may be shorter, focusing on specific phases of treatment.

Ongoing Clinical Trials on Paltusotine

  • Efficacy and Safety Study of Paltusotine for Adults with Carcinoid Syndrome due to Well-Differentiated Neuroendocrine Tumors

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Germany Ireland Italy +4

  • Study on the Long-Term Safety and Efficacy of Paltusotine for Patients with Acromegaly

    Not recruiting

    1 1
    Investigated drugs:
    Germany Greece Hungary

  • Study on the Safety and Effects of Paltusotine and Octreotide Acetate for Patients with Carcinoid Syndrome

    Not recruiting

    1 1 1
    Investigated drugs:
    Poland

  • Study on the Safety and Effectiveness of Paltusotine for Patients with Acromegaly

    Not recruiting

    1 1
    Investigated drugs:
    Belgium Bulgaria France Hungary Italy Poland

  • Study on the Effects of Paltusotine for Patients with Untreated Acromegaly

    Not recruiting

    1 1
    Investigated drugs:
    Bulgaria France Germany Greece Hungary Italy +1

Glossary

  • Acromegaly: A hormonal disorder that develops when the pituitary gland produces too much growth hormone during adulthood. It results in the gradual enlargement of body tissues, including the hands and feet.
  • Carcinoid Syndrome: A group of symptoms associated with carcinoid tumors, which are slow-growing cancers usually found in the gastrointestinal tract. Symptoms may include flushing of the face, diarrhea, and heart problems.
  • Somatostatin: A hormone that regulates the endocrine system and affects neurotransmission and cell proliferation via interaction with G protein-coupled somatostatin receptors.
  • Insulin-like Growth Factor-1 (IGF-1): A hormone similar in molecular structure to insulin, playing an important role in growth and development. It is often used as a marker to monitor acromegaly treatment.
  • Growth Hormone (GH): A peptide hormone that stimulates growth, cell reproduction, and cell regeneration in humans and other animals. Excessive production can lead to acromegaly.
  • Upper Limit of Normal (ULN): The highest value of a physiological measurement that is considered normal or healthy in a population. In these trials, it's often used as a reference point for IGF-1 levels.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Treatment-Emergent Adverse Events (TEAEs): Any unfavorable and unintended sign, symptom, or disease that emerges or worsens after starting a medical treatment.
  • Placebo: An inactive substance that looks like the drug being tested and is used as a control in clinical trials to determine the effectiveness of a medication.
  • Randomized Controlled Trial: A type of scientific experiment where participants are randomly assigned to different treatment groups, including a control group, to compare the effects of interventions.

References